Literature DB >> 30926406

Cardiac Segmental Strain Analysis in Pediatric Left Ventricular Noncompaction Cardiomyopathy.

Alisa Arunamata1, Jesse Stringer2, Sowmya Balasubramanian2, Theresa A Tacy2, Norman H Silverman2, Rajesh Punn2.   

Abstract

BACKGROUND: Left ventricular noncompaction cardiomyopathy (LVNC) is characterized by prominent left ventricular trabeculations, often leading to myocardial dysfunction and death or heart transplantation. Although diagnostic echocardiographic criteria exist for LVNC, segmental speckle-tracking strain patterns have not been described in pediatric LVNC. The objectives of this study were to characterize segmental noncompaction, evaluate segmental speckle-tracking strain, and characterize peak strain values in children with LVNC with adverse clinical outcomes.
METHODS: Echocardiographic noncompaction/compaction ratios and segmental radial, circumferential, and longitudinal strain were measured retrospectively in children with LVNC (January 2000 to June 2013). Segmental strain of the cohort was compared with that in control subjects matched by age and body surface area.
RESULTS: One hundred one pediatric patients with LVNC were included (median age 2.8 years; range, 0-19.4 years); 71 patients survived (benign group) and 30 patients did not survive or required heart transplantation (adverse group). The adverse group was younger at diagnosis (P = .03), with lower ejection fractions (P < .0001) compared with the benign group. Both groups demonstrated increased noncompaction/compaction ratios within apical segments, with significantly increased involvement in antero- and inferolateral midpapillary segments in the adverse group (P < .005). Radial, circumferential, and longitudinal strain of nearly all left ventricular segments were significantly decreased in the adverse compared with the benign group and in pediatric LVNC patients compared with control subjects. Global radial (7.4 ± 9.7% vs 19.6 ± 16.5%, P < .0001), circumferential (-8.4 ± 7.0% vs -18.9 ± 6.9%, P < .0001), and longitudinal (-7.1 ± 5.2% vs -11.8 ± 5.3%, P < .0001) strain were all significantly decreased in the adverse group compared with the benign group.
CONCLUSIONS: Segmental radial, circumferential, and longitudinal strain are decreased in pediatric patients with LVNC compared with control subjects and lowest in those with adverse compared with benign outcomes. LVNC appears to be a global disease affecting deformation in all regions, including compacted myocardial segments.
Copyright © 2019 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  LVNC; Left ventricular noncompaction; Pediatric; Speckle-tracking strain

Year:  2019        PMID: 30926406     DOI: 10.1016/j.echo.2019.01.014

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  3 in total

1.  Natural History of Cardiomyopathy in Adult Dogs With Golden Retriever Muscular Dystrophy.

Authors:  Lee-Jae Guo; Jonathan H Soslow; Amanda K Bettis; Peter P Nghiem; Kevin J Cummings; Mark W Lenox; Matthew W Miller; Joe N Kornegay; Christopher F Spurney
Journal:  J Am Heart Assoc       Date:  2019-08-14       Impact factor: 5.501

2.  Overlap phenotypes of the left ventricular noncompaction and hypertrophic cardiomyopathy with complex arrhythmias and heart failure induced by the novel truncated DSC2 mutation.

Authors:  Yubi Lin; Jiana Huang; Zhiling Zhu; Zuoquan Zhang; Jianzhong Xian; Zhe Yang; Tingfeng Qin; Linxi Chen; Jingmin Huang; Yin Huang; Qiaoyun Wu; Zhenyu Hu; Xiufang Lin; Geyang Xu
Journal:  Orphanet J Rare Dis       Date:  2021-11-24       Impact factor: 4.123

3.  Left and Right Ventricular Morphology, Function and Myocardial Deformation in Children with Left Ventricular Non-Compaction Cardiomyopathy: A Case-Control Cardiovascular Magnetic Resonance Study.

Authors:  Jędrzej Sarnecki; Agata Paszkowska; Joanna Petryka-Mazurkiewicz; Agata Kubik; Janusz Feber; Elżbieta Jurkiewicz; Lidia Ziółkowska
Journal:  J Clin Med       Date:  2022-02-19       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.